JMI LABS IS NOW PART OF LEARN MORE

Antimicrobial Activity of GT-1, a Novel Siderophore Cephalosprin, Tested against Multidrug-Resistant Pseudomonas aeruginosa and Acinetobacter spp. Isolates

Antimicrobial Activity of GT-1, a Novel Siderophore Cephalosprin, Tested against Multidrug-Resistant Pseudomonas aeruginosa and Acinetobacter spp. Isolates. Lead author: LR Duncan, presented at ASM Microbe 2018, June 7-11, Atlanta, GA, USA
# Sunday-577

Fosfomycin Activity against Gram-Negative Isolates from Eastern Europe Collected by the SENTRY Antimicrobial Surveillance Program

Fosfomycin Activity against Gram-Negative Isolates from Eastern Europe Collected by the SENTRY Antimicrobial Surveillance Program. Lead author: D Shortridge, presented at ASM Microbe 2018, June 7-11, Atlanta, GA, USA
# Saturday-632

Omadacycline In Vitro Activity against Skin and Skin Structure, Respiratory, and Urinary Tract Pathogens Collected from the United States and Europe During the 2017 SENTRY Surveillance Program

Omadacycline In Vitro Activity against Skin and Skin Structure, Respiratory, and Urinary Tract Pathogens Collected from the United States and Europe During the 2017 SENTRY Surveillance Program. Lead author: MD Huband. Presented at ASM Microbe 2018, June 7-11, Atlanta, GA, USA
# Saturday-627

Activity of Fosfomycin against Gram-Negative Baseline Bacterial Isolates from Patients in a Phase 3 Complicated Urinary Tract Infection Trial (ZEUS)

Activity of Fosfomycin against Gram-Negative Baseline Bacterial Isolates from Patients in a Phase 3 Complicated Urinary Tract Infection Trial (ZEUS). Lead author: D Shortridge, presented at ASM Microbe 2018, June 7-11, Atlanta, GA, USA
# Saturday-633

Molecular Characterization of Clinical Trial Isolates Exhibiting Increased MIC Results during Fosfomycin (ZTI-01) Treatment in a Phase 2/3 Clinical Trial for Complicated Urinary Tract Infections (ZEUS)

Molecular Characterization of Clinical Trial Isolates Exhibiting Increased MIC Results during Fosfomycin (ZTI-01) Treatment in a Phase 2/3 Clinical Trial for Complicated Urinary Tract Infections (ZEUS). Lead author: RE Mendes, presented at ASM Microbe 2018, June 7-11, Atlanta, GA, USA
# Saturday-637

Activity of Plazomicin and Comparator Agents Tested against Contemporary Clinical Isolates Collected Worldwide

Activity of Plazomicin and Comparator Agents Tested against Contemporary Clinical Isolates Collected Worldwide. Lead author: M Castanheira, presented at ASM Microbe 2018, June 7-11, Atlanta, GA, USA
# Saturday-645

Distribution of β-Lactamase Resistance Genes and Lineage Background in Clinical Isolates Producing Extended-Spectrum β-Lactamases by High-Resolution Genomic Analysis

Distribution of β-Lactamase Resistance Genes and Lineage Background in Clinical Isolates Producing Extended-Spectrum β-Lactamases by High-Resolution Genomic Analysis. Lead author: RE Mendes, presented at ASM Microbe 2018, June 7-11, Atlanta, GA, USA
# Saturday-426

Correlation between Broth Microdilution and Disk Diffusion Methods Results When Testing Ceftaroline against Methicillin-Resistant Staphylococcus aureus and Molecular Characterization of Isolates with Elevated Ceftaroline MIC Results

Correlation between Broth Microdilution and Disk Diffusion Methods Results When Testing Ceftaroline against Methicillin-Resistant Staphylococcus aureus and Molecular Characterization of Isolates with Elevated Ceftaroline MIC Results. Lead author: HS Sader, presented at ASM Microbe 2018, June 7-11, Atlanta, GA, USA
# Saturday-214

Molecular Characterization of Resistance Mechanisms Associated with Pleuromutilins Among Gram-Positive Clinical Isolates From the Worldwide SENTRY Surveillance Studies for Lefamulin

Molecular Characterization of Resistance Mechanisms Associated with Pleuromutilins Among Gram-Positive Clinical Isolates From the Worldwide SENTRY Surveillance Studies for Lefamulin. Lead author: RE Mendes, presented at ASM Microbe 2018, June 7-11, Atlanta, GA, USA
# Saturday-642

Current Assessment of Oritavancin Activity against Multidrug-Resistant Enterococcal Clinical Isolates

Current Assessment of Oritavancin Activity against Multidrug-Resistant Enterococcal Clinical Isolates. Lead author: RE Mendes, presented at ASM Microbe 2018, June 7-11, Atlanta, GA, USA
# Friday-452

In Vitro Activity of Tedizolid and Comparator Agents Tested against Gram-Positive Isolates Causing Serious Infections in Hospitalized Patients in the United States and Europe

In Vitro Activity of Tedizolid and Comparator Agents Tested against Gram-Positive Isolates Causing Serious Infections in Hospitalized Patients in the United States and Europe. Lead author: RE Mendes, presented at ASM Microbe 2018, June 7-11, Atlanta, GA, USA
# Friday-453

In Vitro Activity of a Novel Extended-Spectrum β-Lactamase Inhibitor, AAI101, in Combination with Cefepime, against Enterobacteriaceae Isolates Collected during 2016

In Vitro Activity of a Novel Extended-Spectrum β-Lactamase Inhibitor, AAI101, in Combination with Cefepime, against Enterobacteriaceae Isolates Collected during 2016. Lead author: MD Huband, presented at ASM Microbe 2018, June 7-11, Atlanta, GA, USA
# Friday-601

Activity of Telavancin against a Contemporary Collection of Staphylococcus aureus Clinical Isolates from All 9 US Census Bureau Divisions

Activity of Telavancin against a Contemporary Collection of Staphylococcus aureus Clinical Isolates from All 9 US Census Bureau Divisions. Lead author: LR Duncan, presented at ASM Microbe 2018, June 7-11, Atlanta, GA, USA
# Friday-416

Twenty-Year Trends in Antibiotic Susceptibility among Staphylococcus aureus from the SENTRY Antimicrobial Surveillance Program

Twenty-Year Trends in Antibiotic Susceptibility among Staphylococcus aureus from the SENTRY Antimicrobial Surveillance Program. Lead author: DJ Diekema, presented at ASM Microbe 2018, June 7-11, Atlanta, GA, USA
# Friday-425

Antimicrobial Susceptibility of Streptococcus pneumoniae from North America, Europe, Asia, and Latin America: Results from 20 Years of the SENTRY Antimicrobial Surveillance Program (1997-2016)

Antimicrobial Susceptibility of Streptococcus pneumoniae from North America, Europe, Asia, and Latin America: Results from 20 Years of the SENTRY Antimicrobial Surveillance Program (1997-2016). Lead author: HS Sader, presented at ASM Microbe 2018, June 7-11, Atlanta, GA, USA
# Friday-447

Temporal and Geographic Variation in Antimicrobial Susceptibility and Resistance Patterns of Enterococci: Results from the SENTRY Antimicrobial Surveillance Program, 1997-2016

Temporal and Geographic Variation in Antimicrobial Susceptibility and Resistance Patterns of Enterococci: Results from the SENTRY Antimicrobial Surveillance Program, 1997-2016. Lead author: MA Pfaller, presented at ASM Microbe 2018, June 7-11, Atlanta, GA, USA
# Friday-450

Activity of a Long-Acting Echinocandin Rezafungin (CD101) and Comparator Antifungal Agents Tested against Contemporary Invasive Fungal Isolates: SENTRY 2016

Activity of a Long-Acting Echinocandin Rezafungin (CD101) and Comparator Antifungal Agents Tested against Contemporary Invasive Fungal Isolates: SENTRY 2016. Lead author: M Castanheira, presented at ASM Microbe 2018, June 7-11, Atlanta, GA, USA
# Friday-485

Evolving oxazolidinone resistance mechanisms in a worldwide collection of enterococcal clinical isolates: results from the SENTRY Antimicrobial Surveillance Program.

Evolving oxazolidinone resistance mechanisms in a worldwide collection of enterococcal clinical isolates: results from the SENTRY Antimicrobial Surveillance Program. by Deshpande LM, Castanheira M, Flamm RK and Mendes RE published in J Antimicrob Chemother. 2018: 73 (9); 2314-2322

In vitro activity of plazomicin against Gram-negative and Gram-positive isolates collected from United States hospitals and comparative activity of aminoglycosides against carbapenem-resistant Enterobacteriaceae and isolates carrying carbapenemase genes.

In vitro activity of plazomicin against Gram-negative and Gram-positive isolates collected from United States hospitals and comparative activity of aminoglycosides against carbapenem-resistant Enterobacteriaceae and isolates carrying carbapenemase genes. by Castanheira M, Davis AP, Mendes RE, Serio AW, Krause KM and Flamm RK published in Antimicrob. Agents Chemother. 2018; 62 (8): e00313

Antimicrobial activity of ceftolozane-tazobactam tested against Enterobacteriaceae and Pseudomonas aeruginosa collected from patients with bloodstream infections isolated in United States hospitals (2013-2015) as part of the program to assess ceftolozane-tazobactam susceptibility (PACTS) surveillance program.

Antimicrobial activity of ceftolozane-tazobactam tested against Enterobacteriaceae and Pseudomonas aeruginosa collected from patients with bloodstream infections isolated in United States hospitals (2013-2015) as part of the program to assess ceftolozane-tazobactam susceptibility (PACTS) surveillance program. by Shortridge D, Pfaller MA, Castanheira M and Flamm RK published in Diagn. Microbiol. Infect. Dis.: in press, 2018.

Ceftazidime-avibactam antimicrobial activity and spectrum when tested against Gram-negative organisms from pediatric patients: Results from the INFORM Surveillance Program (United States, 2011-2015).

Ceftazidime-avibactam antimicrobial activity and spectrum when tested against Gram-negative organisms from pediatric patients: Results from the INFORM Surveillance Program (United States, 2011-2015). by Sader HS, Huband MD, Duncan LR and Flamm RK published in Pediatr. Infect. Dis. 2018; J. 37 (6): 549-554

Antimicrobial activity of oritavancin and comparator agents when tested against Gram-positive bacterial isolates causing infections in cancer patients (2014-16).

Antimicrobial activity of oritavancin and comparator agents when tested against Gram-positive bacterial isolates causing infections in cancer patients (2014-16). by Pfaller MA, Sader HS, Castanheira M, Flamm RK and Mendes RE published in J. Antimicrob. Chemother. 2018; 73 (4): 916-922

Oritavancin in vitro activity against gram-positive organisms from European and United States medical centers: results from the SENTRY Antimicrobial Surveillance Program for 2010-2014.

Oritavancin in vitro activity against gram-positive organisms from European and United States medical centers: results from the SENTRY Antimicrobial Surveillance Program for 2010-2014. by Pfaller MA, Sader HS, Flamm RK, Castanheira M and Mendes RE published in Diagn. Microbiol. Infect. Dis. 2018; 91 (2): 199-204

Molecular beta-lactamase characterization of gram-negative pathogens recovered from patients enrolled in the ceftazidime-avibactam phase 3 trials (RECAPTURE 1 and 2) for complicated urinary tract infections: Efficacies analysed against susceptible and resistant subsets.

Molecular beta-lactamase characterization of gram-negative pathogens recovered from patients enrolled in the ceftazidime-avibactam phase 3 trials (RECAPTURE 1 and 2) for complicated urinary tract infections: Efficacies analysed against susceptible and resistant subsets. by Mendes RE, Castanheira M, Woosley LN, Stone GG, Bradford PA and Flamm RK published in Int. J. Antimicrob. Agents. 2018; 52 (2) 287-292

Antimicrobial activity of murepavadin tested against clinical isolates of Pseudomonas aeruginosa from the United States, Europe, and China.

Antimicrobial activity of murepavadin tested against clinical isolates of Pseudomonas aeruginosa from the United States, Europe, and China. by Sader HS, Dale GE, Rhomberg PR and Flamm RK published in Antimicrob. Agents Chemother. 2018; 62 (7): e00311

Direct in vitro comparison of the prodrug isavuconazonium sulfate with the isavuconazole active compound against Aspergillus spp. and 2 rare moulds.

Direct in vitro comparison of the prodrug isavuconazonium sulfate with the isavuconazole active compound against Aspergillus spp. and 2 rare moulds. by Pfaller MA, Rhomberg PR and Castanheira M published in Diagn. Microbiol. Infect. Dis. 2018: 92 (1); 43-45

A systematic approach to the selection of the appropriate avibactam concentration for use with ceftazidime in broth microdilution susceptibility testing.

A systematic approach to the selection of the appropriate avibactam concentration for use with ceftazidime in broth microdilution susceptibility testing. by Bradford PA, Huband MD and Stone GG published in Antimicrob. Agents Chemother.: in press, 2018.

Antimicrobial susceptibility of Enterobacteriaceae and Pseudomonas aeruginosa isolates from United States medical centers stratified by infection type: Results from the International Network for Optimal Resistance Monitoring (INFORM) surveillance program, 2015-2016.

Antimicrobial susceptibility of Enterobacteriaceae and Pseudomonas aeruginosa isolates from United States medical centers stratified by infection type: Results from the International Network for Optimal Resistance Monitoring (INFORM) surveillance program, 2015-2016. by Sader HS, Castanheira M, Duncan LR and Flamm RK published in Diagn. Microbiol. Infect. Dis. 2018: 92 (1); 69-74

Cefepime-AAI101 and cefepime MIC quality control ranges using a CLSI M23-A5 multi-laboratory study design.

Cefepime-AAI101 and cefepime MIC quality control ranges using a CLSI M23-A5 multi-laboratory study design. Lead author: MD Huband, presented at 28th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) 2018, April 21-24, Madrid, Spain
# P2492

Antimicrobial activity of ceftolozane-tazobactam tested against contemporary (2012-2017) Gram-negative isolates from patients hospitalised with pneumonia in European medical centres.

Antimicrobial activity of ceftolozane-tazobactam tested against contemporary (2012-2017) Gram-negative isolates from patients hospitalised with pneumonia in European medical centres. Lead author: D Shortridge, presented at the 28th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) 2018, April 21-24, Madrid, Spain
# P2432

Activity of ceftolozane-tazobactam and comparators when tested against bacterial surveillance isolates collected from paediatric patients in Europe during 2012-2017 as part of a global surveillance program.

Activity of ceftolozane-tazobactam and comparators when tested against bacterial surveillance isolates collected from paediatric patients in Europe during 2012-2017 as part of a global surveillance program. Lead author: D Shortridge, presented at the 28th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) 2018, April 21-24, Madrid, Spain
# P2434

Antimicrobial activity of ceftolozane-tazobactam tested against contemporary (2012-2017) P. aeruginosa isolates from hospitalised patients in European medical centres.

Antimicrobial activity of ceftolozane-tazobactam tested against contemporary (2012-2017) P. aeruginosa isolates from hospitalised patients in European medical centres. Lead author: D Shortridge, presented at the 28th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) 2018, April 21-24, Madrid, Spain
# P2431

Antimicrobial activity of murepavadin tested against clinical isolates of Pseudomonas aeruginosa collected in Europe, United States and China.

Antimicrobial activity of murepavadin tested against clinical isolates of Pseudomonas aeruginosa collected in Europe, United States and China. Lead author: HS Sader, presented at the 28th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) 2018, Madrid, Spain
# P1662

Frequency of occurrence and antimicrobial susceptibility of bacteria isolated from patients hospitalised with community-acquired bacterial pneumonia: Evaluation of ceftaroline potency and antimicrobial spectrum.

Frequency of occurrence and antimicrobial susceptibility of bacteria isolated from patients hospitalised with community-acquired bacterial pneumonia: Evaluation of ceftaroline potency and antimicrobial spectrum. Lead author: HS Sader presented at the 28th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) 2018, April 21-24, Madrid, Spain
# P1817

Community-acquired skin and soft tissue infection in Europe, Asia and Latin America: Frequency of organism occurrence and antimicrobial activity of ceftaroline and comparator agents.

Community-acquired skin and soft tissue infection in Europe, Asia and Latin America: Frequency of organism occurrence and antimicrobial activity of ceftaroline and comparator agents. Lead author: HS Sader, presented at the 28th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) 2018, April 21-24, Madrid, Spain
# P1805

In vitro activity of omadacycline and comparators against Gram-positive and -negative clinical isolates (including resistant organism subsets) collected in 2017 from patients in European medical centres: SENTRY Surveillance Program results.

In vitro activity of omadacycline and comparators against Gram-positive and -negative clinical isolates (including resistant organism subsets) collected in 2017 from patients in European medical centres: SENTRY Surveillance Program results. Lead author: MD Huband, presented in European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) 2018, April 21-24, Madrid, Spain
# P1822

Evaluation of tedizolid activity against Gram-positive clinical isolates causing pneumonia in Europe and surrounding areas (2017-2017).

Evaluation of tedizolid activity against Gram-positive clinical isolates causing pneumonia in Europe and surrounding areas (2017-2017). Lead author: RE Mendes, presented at the 28th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) 2018, April 21-24, Madrid, Spain
# P1807

Murepavadin activity tested against contemporary (2016-2017) clinical isolates of extensively drug-resistant (XDR) Pseudomonas aeruginosa.

Murepavadin activity tested against contemporary (2016-2017) clinical isolates of extensively drug-resistant (XDR) Pseudomonas aeruginosa. Lead author: HS Sader, presented at the 28th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) 2018, Madrid, Spain
# P1661

Antimicrobial activity of ceftazidime and piperacillin-tazobactam tested in combination with a potentiator molecule (SPR741) against Enterobacteriaceae causing urinary tract infections.

Antimicrobial activity of ceftazidime and piperacillin-tazobactam tested in combination with a potentiator molecule (SPR741) against Enterobacteriaceae causing urinary tract infections. Lead author: RE Mendes, presented at the 28th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) 2018, April 21-24, Madrid, Spain
# P1671

Evaluation of synergistic effects of a potentiator molecule (SPR741) when tested in combination with a series of β-lactam agents against a challenge set of Gram-negative pathogens.

Evaluation of synergistic effects of a potentiator molecule (SPR741) when tested in combination with a series of β-lactam agents against a challenge set of Gram-negative pathogens. Lead author: RE Mendes, presented at the 28th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) 2018, April 21-24, Madrid, Spain
# P1672

Activity of telavancin against a global collection of multidrug-resistant Gram-positive isolates and ceftaroline-nonsusceptible Staphylococcus aureus (2015-2017).

Activity of telavancin against a global collection of multidrug-resistant Gram-positive isolates and ceftaroline-nonsusceptible Staphylococcus aureus (2015-2017). Lead author: LR Duncan, presented at the 28th European Congress of Clinical Microbiology and Infections Diseases (ECCMID) 2018, April 21-24, Madrid, Spain
# P1808

Current in vitro analysis of tedizolid activity against Gram-positive clinical isolates causing bloodstream infections in Europe and surrounding areas (2014-2017).

Current in vitro analysis of tedizolid activity against Gram-positive clinical isolates causing bloodstream infections in Europe and surrounding areas (2014-2017). Lead author: RE Mendes, presented at the 28th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) 2018, April 21-24, Madrid, Spain
# P1806

Geographic and temporal patterns of antimicrobial resistance in Pseudomonas aeruginosa from the SENTRY Surveillance Program, 1997-2016.

Geographic and temporal patterns of antimicrobial resistance in Pseudomonas aeruginosa from the SENTRY Surveillance Program, 1997-2016. Lead author: D Shortridge, presented at the 28th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) 2018, April 21-24, Madrid, Spain
# P1140

Geographic and temporal variation on the frequency of occurrence and antimicrobial susceptibility of bacteria isolated from patients hospitalised with bacterial pneumonia: Results from 20 years of the SENTRY Program (1997-2016).

Geographic and temporal variation on the frequency of occurrence and antimicrobial susceptibility of bacteria isolated from patients hospitalised with bacterial pneumonia: Results from 20 years of the SENTRY Program (1997-2016). Lead author: HS Sader, presented at the 28th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) 2018, April 21-24, Madrid, Spain
# P0929

The worldwide panorama of Acinetobacter baumannii group and Stenotrophomonas maltophilia in the last 20 years: Results from the SENTRY Antimicrobial Surveillance Program (1997-2016).

The worldwide panorama of Acinetobacter baumannii group and Stenotrophomonas maltophilia in the last 20 years: Results from the SENTRY Antimicrobial Surveillance Program (1997-2016). Lead author: AC Gales, presented at the 28th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) 2018, April 21-24, Madrid, Spain
# P1104

Changes in serotype distribution and antimicrobial nonsusceptibility in Streptococcus pneumoniae causing pneumonia in adults from 4 European countries following paediatric immunization with 13-valent pneumococcal conjugate vaccine (PCV13).

Changes in serotype distribution and antimicrobial nonsusceptibility in Streptococcus pneumoniae causing pneumonia in adults from 4 European countries following paediatric immunization with 13-valent pneumococcal conjugate vaccine (PCV13). Lead author: RE Mendes, presented at the 28th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), April 21-24, Madrid, Spain
# P0606

In vitro evaluation of delafloxacin activity when tested against contemporary European community-acquired bacterial respiratory tract infection isolates (2014-2017): results from the SENTRY Antimicrobial Surveillance Program.

In vitro evaluation of delafloxacin activity when tested against contemporary European community-acquired bacterial respiratory tract infection isolates (2014-2017): results from the SENTRY Antimicrobial Surveillance Program. Lead author: D Shortridge, presented at the 28th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) 2018, April 21-24, Madrid, Spain
# P0599

Variations in the occurrence of ESBL, CRE and MDR phenotypes among Enterobacteriaceae isolates: Results from 20 years of the SENTRY Antimicrobial Surveillance Program.

Variations in the occurrence of ESBL, CRE and MDR phenotypes among Enterobacteriaceae isolates: Results from 20 years of the SENTRY Antimicrobial Surveillance Program. Lead author: M Castanheira, presented at the 28th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) 2018, April 21-24, Madrid, Spain
# P1073

Activity of meropenem-vaborbactam against Enterobacteriaceae isolates collected during 2016.

Activity of meropenem-vaborbactam against Enterobacteriaceae isolates collected during 2016. Lead author: M Castanheira, presented at the 28th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) 2018, April 21-24, Madrid, Spain
# P1043

Antimicrobial activity of omadacycline tested against clinical bacterial isolates collected from hospitals in China, including Hong Kong, and Taiwan: Results from the SENTRY Antimicrobial Surveillance Program (2013-2016).

Antimicrobial activity of omadacycline tested against clinical bacterial isolates collected from hospitals in China, including Hong Kong, and Taiwan: Results from the SENTRY Antimicrobial Surveillance Program (2013-2016). Lead author HS Sader, presented at the 28th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) 2018, April 21-24, Madrid, Spain
# P0102